ClinicalTrials.Veeva

Menu

Chemsex Engagement and HIV Biomedical Prevention in MSM

The Chinese University of Hong Kong logo

The Chinese University of Hong Kong

Status

Completed

Conditions

Recreational Drug Use

Treatments

Diagnostic Test: HIV test

Study type

Observational

Funder types

Other

Identifiers

NCT05031832
MSS344R

Details and patient eligibility

About

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Enrollment

733 patients

Sex

Male

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • aged 18 or above
  • male
  • have had sex with men since 2019
  • could be communicated in English or Chinese

Exclusion criteria

  • failed to provide consent

Trial design

733 participants in 2 patient groups

HIV-negative
Treatment:
Diagnostic Test: HIV test
HIV-positive

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems